RxDoctor Payments Data

David Amaro-Driedger, MD

Interventional Pain Medicine · Killeen, TXNPI 1447755251

Payments from drug & device makers

$3,715in general payments, 2019–2025

Across 70 payments — averaging $53.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Saluda Medical Americas, Inc.$129
  • Averitas Pharma Inc.$125
  • Boston Scientific$96
  • Pfizer$76
  • Stryker$66
  • plus $84 from 3 others

What the payments were for

  • Speaking & faculty fees$371%
  • Food & beverage$3,67899%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,715 in reported general payments places this provider in the 35th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$263,804
Medicare patients
384
Services billed
2,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,526$85,263
Xtampza ErOxycodone Myristate28$17,898
OxycontinOxycodone Hcl37$14,995
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen521$13,719
Hysingla ErHydrocodone Bitartrate25$13,522
Morphine Sulfate ErMorphine Sulfate300$9,017
Oxycodone Hcl409$7,271
Buprenorphine14$3,809
Fentanyl27$2,874
Hydromorphone Hcl124$2,381
Tizanidine Hcl53$2,129
Gabapentin112$1,853
Pregabalin98$1,536
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl15$1,276
Methadone Hcl55$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$23$17,89828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Killeen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →